---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000915"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:47:57.950997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M

## Summary
- Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).
- GAAP net income Q4 $6.8M vs loss $9.1M; Adjusted EBITDA Q4 $22.5M vs $2.6M.
- IHEEZO unit demand +43% QoQ to 49,130 units; VEVYE prescriptions +44% QoQ, approaching 5% DED market share.
- TRIESENCE awarded CMS transitional pass-through (April 2025-2028); five-year supply agreement with CMO; next-gen NDA by 2027.
- FY2025 revenue guidance 'over $280M' (>40% YoY); cash $47.2M; met leverage ratio, avoided warrant issuance.

## SEC filing metadata
- accession: 0001641172-25-000915
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/0001641172-25-000915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000915
- JSON: https://secwatch.observer/filing/0001641172-25-000915.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.